NCT00159484View on ClinicalTrials.gov

Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2017

Conditions
Colon CancerColorectal Cancer
Interventions
DRUG

EPO906, celecoxib

EPO906 IV, every three weeks, celecoxib by mouth twice a day every day

Trial Locations (1)

90033

U.S.C./Norris Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of Southern California

OTHER

NCT00159484 - Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter